Table III.
Candidate agents in investigation, for patients with BCR-ABL1 positive leukemias intolerant/refactory/resistant to second generation TKIs or harboring the T315 mutantion.
| Novel kinase inhibitors |
| • Ponatinib (AP24534) |
| • DCC-2036 |
| • PHA-739258 |
|
Omacetaxine (Homoharingtonine) |
| Other approaches |
| • HSP-90 inhibitors |
| • Histone deacetylase inhibitors |